NCT06938711View on ClinicalTrials.gov

A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2023

Primary Completion Date

November 30, 2023

Study Completion Date

December 31, 2023

Conditions
Breast Cancer
Interventions
DRUG

Elacestrant

Elacestrant 200mg once daily oral dosing in cycles of 28 days.

DRUG

Onapristone

Onapristone 40mg twice daily oral dosing in cycles of 28 days.

Trial Locations (1)

37203

Sarah Cannon Research Institute, Nashville

Sponsors
All Listed Sponsors
lead

Context Therapeutics Inc.

INDUSTRY

NCT06938711 - A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter